Spondin-2 inhibits EC migration and tube formation and its over-expression impairs angiogenesis and tumor growth, suggesting that it may function as a potential target for anti-angiogenic therapy as well as a biomarker for CRC [108]. The gene discussed is SPON2; the disease is neoplasm.